Oncology Venture A/S has entered into a SEK 200 million investment and financing agreement with European High Growth Opportunities Securitization Fund. The facility is based on the issuance of convertible notes and warrants, and is established to secure Oncology Venture’s further development and commercialization of its highly promising pipeline of cancer drugs.

Mazanti Transactions has assisted Oncology Venture A/S throughout the process.